关于动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇安全低值的探讨

Discussion on the Safe Low Value of Low-Density Lipoprotein Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

动脉粥样硬化性心血管疾病(ASCVD)是导致人群死亡和致残的主要原因,临床研究已证实,在所有可改变的心血管危险因素中,低密度脂蛋白胆固醇(LDL-C)升高与ASCVD的发生最为相关。本文回顾了各种降脂治疗的临床研究,总结了不同研究中ASCVD患者LDL-C的安全低值,分析表明低水平LDL-C既可保证临床治疗的有效性,又不增加临床风险,目前认为ASCVD患者LDL-C的安全低值为<1.40 mmol/L,这为ASCVD患者的临床治疗提供了参考。

Atherosclerotic cardiovascular disease(ASCVD)is the leading cause of death and disability in the population,and it has been clinically demonstrated that among all modifiable cardiovascular risk factors,elevated low-density lipoprotein cholesterol(LDL-C)is most associated with the development of ASCVD.This paper reviews the clinical studies of various lipid-lowering treatments,and summarizes the safe and low levels of LDL-C in ASCVD patients in different studies.Analysis shows that low levels of LDL-C can not only ensure the effectiveness of clinical treatment,but also do not increase clinical risks.Currently,it is believed that the safe low value of LDL-C in ASCVD patients is less than 1.40 mmol/L,which provides a reference for the clinical treatment of ASCVD patients.